Compare Funko Inc (FNKO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Incyte Corporation — how do they compare? Funko Inc trades at $6.43 (market cap $363.97M), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 62.8× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Incyte Corporation for 33 Days on average.
| FNKO | INCY | |
|---|---|---|
Market Cap | $363.97M | $22.85B |
Volume | 1,422,651 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $129.93 |
52-Week Low | $2.81 | $83.80 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $584.62M | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.44, up 2.06% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised EBITDA guidance, though profitability remains challenged with negative net margins. Analyst sentiment is mixed with a 'Hold' consensus and $7.58 price target, representing 17.7% upside potential from current levels.
Investment outlook balances operational improvements against persistent profitability challenges. The stock offers potential upside from continued execution of the 'Make Culture POP!' strategy and margin expansion, but faces risks from consumer discretionary spending volatility and competitive pressures in the collectibles market.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
